ArticleCureus2026
Navigating the Diagnosis of Atypical Still's Disease in the Absence of the Characteristic Rash.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Although adult-onset Still's disease (AOSD) typically presents with a triad of fever, rash, and arthritis, atypical manifestations can significantly hinder the diagnostic process of fever of unknown origin (FUO). We describe the case of a 57-year-old woman who presented with prolonged fever, serositis, and extreme hyperferritinemia (ferritin levels 117,904 ng/mL), further complicated by aseptic encephalitis. Following a comprehensive diagnostic workup to exclude infectious, neoplastic, and other autoimmune etiologies, the patient was evaluated using the Yamaguchi criteria. Despite the absence of the characteristic salmon-pink rash, the diagnosis of atypical AOSD was confirmed as the patient fulfilled three major (fever, arthralgia, and neutrophilic leukocytosis) and two minor (lymphadenopathy and/or splenomegaly and the absence of rheumatoid factor and antinuclear antibodies) criteria. Clinical remission and resolution of neurological symptoms were achieved through treatment with systemic corticosteroids and tocilizumab (8 mg/kg). This case emphasizes that AOSD remains a critical differential diagnosis in FUO even without an evanescent rash and highlights the potential for severe neurological involvement. Our findings support the utility of the Yamaguchi criteria in atypical presentations and illustrate the rapid therapeutic response to interleukin-6 inhibition in this clinical context.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.